Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

URN to cite this document:: urn:nbn:de:bvb:355-epub-538974
DOI to cite this document:: 10.5283/epub.53897

Carnell, George W.

; Billmeier, Martina ; Vishwanath, Sneha

; Suau Sans, Maria ; Wein, Hannah ; George, Charlotte L. ; Neckermann, Patrick

; Del Rosario, Joanne Marie M.

; Sampson, Alexander T.

; Einhauser, Sebastian

; Aguinam, Ernest T.

; Ferrari, Matteo ; Tonks, Paul ; Nadesalingam, Angalee ; Schütz, Anja ; Huang, Chloe Qingzhou ; Wells, David A.

; Paloniemi, Minna ; Jordan, Ingo

; Cantoni, Diego

; Peterhoff, David

; Asbach, Benedikt ; Sandig, Volker ; Temperton, Nigel

; Kinsley, Rebecca ; Wagner, Ralf ; Heeney, Jonathan L.

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 06 Mar 2023 15:32

Alternative links to fulltext:DOI Publisher Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA viruses, new variants have evolved and quickly replaced the original wild-type SARS-CoV-2, leading ...